Literature DB >> 17003307

Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes.

Peter J Dyck1, Jenny L Davies, Vicki M Clark, William J Litchy, P James B Dyck, Christopher J Klein, Robert A Rizza, John M Pach, Ronald Klein, Timothy S Larson, L Joseph Melton, Peter C O'Brien.   

Abstract

OBJECTIVE: The degree to which chronic glycemic exposure (CGE) (fasting plasma glucose [FPG], HbA1c [A1C], duration of diabetes, age at onset of diabetes, or combinations of these) is associated with or predicts the severity of microvessel complications is unsettled. Specifically, we test whether combinations of components correlate and predict complications better than individual components. RESEARCH DESIGN AND METHODS: Correlations and predictions of CGE and complications were assessed in the Rochester Diabetic Neuropathy Study, a population-based, cross-sectional, and longitudinal epidemiologic survey of 504 patients with diabetes followed for up to 20 years.
RESULTS: In multivariate analysis, A1C and duration of diabetes (and to a lesser degree age at onset of diabetes but not FPG) were the main significant CGE risk covariates for complications. A derived glycemic exposure index (GE(i)) correlated with and predicted complications better than did individual components. Composite or staged measures of polyneuropathy provided higher correlations and better predictions than did dichotomous measures of whether polyneuropathy was present or not. Generally, the mean GE(i) was significantly higher with increasing stages of severity of complications.
CONCLUSIONS: A combination of A1C, duration of diabetes, and age at onset of diabetes (a mathematical index, GE(i)) correlates significantly with complications and predicts later complications better than single components of CGE. Serial measures of A1C improved the correlations and predictions. For polyneuropathy, continuous or staged measurements performed better than dichotomous judgments. Even with intensive assessment of CGE and complications over long times, only about one-third of the variability of the severity of complications is explained, emphasizing the role of other putative risk covariates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003307     DOI: 10.2337/dc06-0525

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  23 in total

1.  Does prediabetes cause small fiber sensory polyneuropathy? Does it matter?

Authors:  C D Kassardjian; P J B Dyck; J L Davies; Rickey E Carter; P J Dyck
Journal:  J Neurol Sci       Date:  2015-05-27       Impact factor: 3.181

2.  Diagnostic performance of two-dimensional shear wave elastography for evaluating tibial nerve stiffness in patients with diabetic peripheral neuropathy.

Authors:  Weixi Jiang; Sirun Huang; Hua Teng; Peipei Wang; Meng Wu; Xia Zhou; Weiwei Xu; Qunxia Zhang; Haitao Ran
Journal:  Eur Radiol       Date:  2018-11-28       Impact factor: 5.315

3.  A controlled study of medial arterial calcification of legs: implications for diabetic polyneuropathy.

Authors:  Joon-Shik Moon; Vicki M Clark; John W Beabout; Ronald G Swee; Peter James Dyck
Journal:  Arch Neurol       Date:  2011-10

4.  Ambulatory screening of diabetic neuropathy and predictors of its severity in outpatient settings.

Authors:  M S Qureshi; M Iqbal; S Zahoor; J Ali; M U Javed
Journal:  J Endocrinol Invest       Date:  2016-11-15       Impact factor: 4.256

Review 5.  Therapeutic strategies for diabetic neuropathy.

Authors:  Ali A Habib; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2010-03       Impact factor: 5.081

Review 6.  DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history.

Authors:  Rodica Pop-Busui; William H Herman; Eva L Feldman; Phillip A Low; Catherine L Martin; Patricia A Cleary; Barbara H Waberski; John M Lachin; James W Albers
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

7.  Low peripheral nerve conduction velocities and amplitudes are strongly related to diabetic microvascular complications in type 1 diabetes: the EURODIAB Prospective Complications Study.

Authors:  Morten Charles; Sabita S Soedamah-Muthu; Solomon Tesfaye; John H Fuller; Joseph C Arezzo; Nishi Chaturvedi; Daniel R Witte
Journal:  Diabetes Care       Date:  2010-09-07       Impact factor: 19.112

8.  A trial of proficiency of nerve conduction: greater standardization still needed.

Authors:  Peter J Dyck; James W Albers; James Wolfe; Charles F Bolton; Nancy Walsh; Christopher J Klein; Andrew J Zafft; James W Russell; Karen Thomas; Jenny L Davies; Rickey E Carter; L Joseph Melton; William J Litchy
Journal:  Muscle Nerve       Date:  2013-07-17       Impact factor: 3.217

Review 9.  Spectrum of diabetic neuropathies.

Authors:  Hideyuki Sasaki; Nobutoshi Kawamura; Peter J Dyck; P James B Dyck; Mikihiro Kihara; Phillip A Low
Journal:  Diabetol Int       Date:  2020-01-08

10.  Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors.

Authors:  Jackie Elliott; Solomon Tesfaye; Nish Chaturvedi; Rajiv A Gandhi; Lynda K Stevens; Celia Emery; John H Fuller
Journal:  Diabetes Care       Date:  2009-07-08       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.